Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Return on Equity (2016 - 2025)

IGC Pharma (IGC) has disclosed Return on Equity for 15 consecutive years, with 0.91% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Equity rose 74.0% to 0.91% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.91%, a 74.0% increase, with the full-year FY2025 number at 1.04%, up 13.0% from a year prior.
  • Return on Equity was 0.91% for Q3 2025 at IGC Pharma, up from 1.02% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.27% in Q2 2021 to a low of 1.75% in Q2 2024.
  • A 5-year average of 0.88% and a median of 0.77% in 2023 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: crashed -98bps in 2024, then skyrocketed 74bps in 2025.
  • IGC Pharma's Return on Equity stood at 0.38% in 2021, then tumbled by -93bps to 0.73% in 2022, then tumbled by -68bps to 1.22% in 2023, then decreased by -6bps to 1.29% in 2024, then grew by 30bps to 0.91% in 2025.
  • Per Business Quant, the three most recent readings for IGC's Return on Equity are 0.91% (Q3 2025), 1.02% (Q2 2025), and 1.13% (Q1 2025).